/
KRRO
$13.20+$0.50 (+3.90%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$183.2M
14M shares
52-week range
$5.20 – $55.89
16% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
1.36%
Moderate
Price (6 mo)
Loading chart…
Change$-2.29
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $28.9M | $37.0M | $14.1M | $0 | $0 | $2.3M | $6.4M |
| Cost of revenue | $654.0K | $16.8M | $1.6M | $3.8M | $0 | $0 | $0 | $4.3M |
| Gross profit | −$654.0K | $12.1M | $35.4M | $10.2M | $0 | $0 | $2.3M | $2.1M |
| Gross margin | — | 41.9% | 95.7% | 72.7% | — | — | 100.0% | 33.0% |
| R&D | $11.6M | $18.3M | $36.7M | $59.3M | $42.2M | $57.3M | $63.6M | $65.6M |
| Operating income | −$18.9M | −$20.7M | −$27.6M | −$84.0M | −$59.0M | −$84.5M | −$91.9M | −$87.3M |
| EBITDA | −$18.4M | −$17.9M | −$24.9M | −$80.1M | −$56.5M | −$80.9M | −$88.3M | −$83.1M |
| Net income | −$19.2M | −$18.7M | −$26.5M | −$84.7M | −$58.0M | −$81.2M | −$83.6M | −$117.3M |
| Net margin | — | -64.8% | -71.7% | -602.0% | — | — | -3680.4% | -1834.5% |
| EPS (diluted) | -30.57 | -30.39 | -41.10 | -4.94 | -227.42 | -53.08 | -9.37 | -12.48 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $562500 | $-5.42 | $-6.89–$-3.51 | 9 |
| 2027 | $214286 | $-5.20 | $-6.33–$-3.08 | 8 |
| 2028 | $1M | $-5.25 | $-7.81–$-2.94 | 8 |
| 2029 | $16M | $-5.80 | $-5.80–$-5.80 | 6 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Korro Bio, Inc. Common Stock
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
www.korrobio.com- Employees
- 49
- IPO / List date
- Nov 6, 2023
- HQ
- CAMBRIDGE, MA
Held by traders on TradeandTell
No one on the platform currently holds KRRO.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 136,227 | $1.5M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded KRRO yet.
